- Home
- CHRS vs MUE Comparison
CHRS vs MUE Comparison
Compare CHRS & MUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- MUE
- Stock Information
- Founded
- CHRS 2010
- MUE 1999
- Country
- CHRS United States
- MUE United States
- Employees
- CHRS N/A
- MUE N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- MUE Investment Bankers/Brokers/Service
- Sector
- CHRS Health Care
- MUE Finance
- Exchange
- CHRS Nasdaq
- MUE Nasdaq
- Market Cap
- CHRS 191.3M
- MUE 227.5M
- IPO Year
- CHRS 2014
- MUE N/A
- Fundamental
- Price
- CHRS $1.32
- MUE $10.26
- Analyst Decision
- CHRS Strong Buy
- MUE
- Analyst Count
- CHRS 4
- MUE 0
- Target Price
- CHRS $5.38
- MUE N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- MUE 62.6K
- Earning Date
- CHRS 03-12-2025
- MUE 01-01-0001
- Dividend Yield
- CHRS N/A
- MUE 4.09%
- EPS Growth
- CHRS N/A
- MUE N/A
- EPS
- CHRS N/A
- MUE N/A
- Revenue
- CHRS $304,340,000.00
- MUE N/A
- Revenue This Year
- CHRS $2.47
- MUE N/A
- Revenue Next Year
- CHRS N/A
- MUE N/A
- P/E Ratio
- CHRS N/A
- MUE N/A
- Revenue Growth
- CHRS 44.19
- MUE N/A
- 52 Week Low
- CHRS $0.66
- MUE $8.53
- 52 Week High
- CHRS $2.87
- MUE $10.17
- Technical
- Relative Strength Index (RSI)
- CHRS 41.91
- MUE 51.92
- Support Level
- CHRS $1.38
- MUE $9.94
- Resistance Level
- CHRS $1.60
- MUE $10.25
- Average True Range (ATR)
- CHRS 0.12
- MUE 0.13
- MACD
- CHRS -0.03
- MUE 0.03
- Stochastic Oscillator
- CHRS 1.10
- MUE 84.62
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. The fund seeks to achieve its investment objective by investing in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes.